Venus Medtech (Hangzhou) Inc. Stock
Equities
2500
CNE100003PJ8
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 HKD | -0.71% | -.--% | -.--% |
May. 13 | Venus Medtech Board Receives Internal Control Review Report from Consultant | MT |
Apr. 01 | Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% | MT |
Sales 2024 * | 730M 101M 787M | Sales 2025 * | 990M 137M 1.07B | Capitalization | 2.26B 312M 2.44B |
---|---|---|---|---|---|
Net income 2024 * | -293M -40.48M -316M | Net income 2025 * | 38M 5.25M 40.98M | EV / Sales 2024 * | 3.26 x |
Net Debt 2024 * | 125M 17.29M 135M | Net Debt 2025 * | 463M 63.97M 499M | EV / Sales 2025 * | 2.75 x |
P/E ratio 2024 * |
-7.89
x | P/E ratio 2025 * |
-56.5
x | Employees | 865 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.87% |
1 day | -0.71% | ||
6 months | +8.70% |
Managers | Title | Age | Since |
---|---|---|---|
Hou-Sen Lim
CEO | Chief Executive Officer | 50 | 16-11-30 |
Fei Wang
DFI | Director of Finance/CFO | 47 | 23-01-03 |
Meirong Liu
BRD | Director/Board Member | 47 | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hou-Sen Lim
CEO | Chief Executive Officer | 50 | 16-11-30 |
Ting Yuk Wu
CHM | Chairman | 69 | 18-11-25 |
Wei Wang
BRD | Director/Board Member | 41 | 18-11-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 112 M€ | +5.40% | - | |
0.00% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +4.54% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-.--% | 316M | |
+10.27% | 126B | |
-5.47% | 11.33B | |
+4.83% | 9.27B | |
+36.49% | 5.5B | |
-25.10% | 4.61B | |
+8.63% | 3.45B | |
-9.81% | 2.81B | |
-10.99% | 2.09B | |
-10.20% | 2.08B |
- Stock Market
- Equities
- 2500 Stock